CRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning a collaboration and license agreement. It was alleged that the respondent breached the agreement by failing to pay amounts related to the respondent’s subsequent drug development agreements with other parties. CRA provided context for drug development and collaboration agreements in the pharmaceutical industry. In addition, CRA evaluated the damages claimed, which relied on a projection of future sales of drugs that had not reached the market.
Damages in Life Sciences Arbitrations
Gregory K. Bell, Andrew Tepperman, and Justin Ho contributed a chapter to Global Arbitration Review’s The Guide to Damages in International Arbitration. Their...